Table 3.
In vitro expansion of Vγ9Vδ2-TCR+ T cells from PBMC of melanoma patients in response to zoledronate.
| Treatment of PBMC | IL-2/IL-15 | CD25+ depleted IL-2/IL-15 |
|---|---|---|
| Donors | 9 | 9 |
| Input of Vγ9+ T cells (x106/106 PBMC)a | 0.0095 ± 0.01 | 0.0095 ± 0.01 |
| DAY 14 CULTURES | ||
| Live cells (%)b | 85 ± 7 | 84 ± 6 |
| CD3+ cells (%)c | 95 ± 4 | 86 ± 15 |
| Vγ9+ T cells (%)c | 54 ± 33 | 56 ± 26 |
| Yield of Vγ9+ T cells (x106/106 PBMC)d | 8.2 ± 7.23 | 2.2 ± 2.72 |
| Expansion folde | 861 ± 723 | 230 ± 272 |
a Initiation of cultures at 106 PBMC per well (24-well plate).
b Live cells defined as Aqua− cells.
c Percentage of total live (Aqua−) cells.
d Number of Vγ9+ T cells per 106 of input PBMC after 14 days of culture.
e Yield of Vγ9+ T cells divided by input Vγ9+ T cells.